Literature DB >> 6326447

The presence of autoantibodies directed to thyroid plasma membrane antigens in sera of patients with thyroid disorders, estimated by the reaction with labelled protein A.

A Gardas, B Czarnocka, J Nauman.   

Abstract

The presence of antithyroid plasma membrane antibodies (ATMA) has been detected in 97% of patients with untreated hyperthyroid Graves' disease, 85% of methimazole treated hyperthyroid Graves' disease, 25% of Hashimoto's thyroiditis and 6.9% of patients with toxic nodular goitre. The ATMA index was negative in all healthy blood donors, in patients with non-toxic nodular goitre, with the thyrocardiac syndrome and with simple obesity. Studies of patients with non-thyroid autoimmune diseases revealed that ATMA is positive in 11% of patients with scleroderma, 17.6% of systemic lupus erythematosus and 16% of rheumatoid arthritis. The amount of immunoglobulin bound to thyroid plasma membranes after pre-incubation with serum from patients with Graves' disease varied from 4.2 to 25.2 pmoles per mg of membrane protein; these values are several times higher than the maximal binding capacity for thyrotrophin which is 1.28 pmole/mg protein. In the majority of the cases studied TSH did not significantly inhibit IgG bound from thyroid plasma membranes. Significant amounts of IgG were displaced by an excess of TSH only in three cases with untreated hyperthyroid Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326447     DOI: 10.1530/acta.0.1050500

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  2 in total

1.  Hyperthyroidism due to Graves' disease and due to autonomous goiter.

Authors:  H Schicha; D Emrich; I Schreivogel
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

2.  Measurement of autoantibodies against human eye muscle plasma membranes in Graves' ophthalmopathy.

Authors:  M Faryna; J Nauman; A Gardas
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.